More on ABCL

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+10.5% Growth)
- Ratings (8.7 Score)
- Holders

Upcoming Events

- Earnings (11/9/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

AbCellera (NQ:ABCL)
Delayed: 11.80 -0.88 (6.94%)
Prev. Close $12.68  
Open$12.68 
52 Wk High$ 
52 Wk Low$ 
Day High$12.68 
Day Low$11.72 
P/E N/A  
EPS$ 
Volume4,111,933 

Friends, Peers and Foes (?): ABSI, SDGR, JAZZ, VRTX, HYFT (more...)

Oct 12, 2026 02:19 AM UBS Starts AbCellera Biologics (ABCL) at Buy
Oct 8, 2026 04:05 PM AbCellera to present Phase 1/2 data on ABCL635 at menopause meeting
Oct 8, 2026 04:05 PM AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
Oct 1, 2026 04:05 PM AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Sep 29, 2026 05:29 AM JPMorgan Starts AbCellera Biologics (ABCL) at Overweight, 'feedback bodes well overall'
Sep 24, 2026 04:59 AM Goldman Sachs Resumes AbCellera Biologics (ABCL) at Neutral
Sep 16, 2026 04:05 PM AbCellera to present Phase 2 data on menopause drug at IMS congress
Sep 16, 2026 04:05 PM AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
Aug 24, 2026 05:22 PM Form 4 AbCellera Biologics Inc. For: Aug 24 Filed by: Hayden Michael R
Aug 19, 2026 08:56 AM Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
View All Articles

Entities mentioned with ABCL

View All Entities